27812347|t|T2-Imaging Changes in the Nigrosome-1 Relate to Clinical Measures of Parkinson's Disease
27812347|a|The nigrosome-1 region of the substantia nigra (SN) undergoes the greatest and earliest dopaminergic neuron loss in Parkinson's disease (PD). As T2-weighted magnetic resonance imaging (MRI) scans are often collected with routine clinical MRI protocols, this investigation aims to determine whether T2-imaging changes in the nigrosome-1 are related to clinical measures of PD and to assess their potential as a more clinically accessible biomarker for PD. Voxel intensity ratios were calculated for T2-weighted MRI scans from 47 subjects from the Parkinson's Progression Markers Initiative database. Three approaches were used to delineate the SN and nigrosome-1: (1) manual segmentation, (2) automated segmentation, and (3) area voxel -based morphometry. Voxel intensity ratios were calculated from voxel intensity values taken from the nigrosome-1 and two areas of the remaining SN. Linear regression analyses were conducted relating voxel intensity ratios with the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) sub-scores for each subject. For manual segmentation, linear regression tests consistently identified the voxel intensity ratio derived from the dorsolateral SN and nigrosome-1 (IR2) as predictive of nBehav (p = 0.0377) and nExp (p = 0.03856). For automated segmentation, linear regression tests identified IR2 as predictive of Subscore IA (nBehav) (p = 0.01134), Subscore IB (nExp) (p = 0.00336), Score II (mExp) (p = 0.02125), and Score III (mSign) (p = 0.008139). For the voxel -based morphometric approach, univariate simple linear regression analysis identified IR2 as yielding significant results for nBehav (p = 0.003102), mExp (p = 0.0172), and mSign (p = 0.00393). Neuroimaging biomarkers may be used as a proxy of changes in the nigrosome-1, measured by MDS-UPDRS scores as an indicator of the severity of PD. The voxel intensity ratio derived from the dorsolateral SN and nigrosome-1 was consistently predictive of non-motor complex behaviors in all three analyses and predictive of non-motor experiences of daily living, motor experiences of daily living, and motor signs of PD in two of the three analyses. These results suggest that T2 changes in the nigrosome-1 may relate to certain clinical measures of PD. T2 changes in the nigrosome-1 may be considered when developing a more accessible clinical diagnostic tool for patients with suspected PD.
27812347	0	10	T2-Imaging	T060	C0412676
27812347	11	18	Changes	T169	C0392747
27812347	26	37	Nigrosome-1	T025	C1512035
27812347	48	65	Clinical Measures	T201	C0683325
27812347	69	88	Parkinson's Disease	T047	C0030567
27812347	93	104	nigrosome-1	T025	C1512035
27812347	119	135	substantia nigra	T023	C0038590
27812347	137	139	SN	T023	C0038590
27812347	177	201	dopaminergic neuron loss	T033	C3550005
27812347	205	224	Parkinson's disease	T047	C0030567
27812347	226	228	PD	T047	C0030567
27812347	234	284	T2-weighted magnetic resonance imaging (MRI) scans	T060	C0412676
27812347	318	326	clinical	T080	C0205210
27812347	327	330	MRI	T060	C0024485
27812347	347	360	investigation	T058	C0220825
27812347	387	397	T2-imaging	T060	C0412676
27812347	398	405	changes	T169	C0392747
27812347	413	424	nigrosome-1	T025	C1512035
27812347	440	457	clinical measures	T201	C0683325
27812347	461	463	PD	T047	C0030567
27812347	471	477	assess	T058	C0184514
27812347	484	493	potential	T080	C3245505
27812347	526	535	biomarker	T201	C0005516
27812347	540	542	PD	T047	C0030567
27812347	544	566	Voxel intensity ratios	T081	C0392762
27812347	572	582	calculated	T052	C1441506
27812347	587	608	T2-weighted MRI scans	T060	C0412676
27812347	635	646	Parkinson's	T047	C0030567
27812347	647	666	Progression Markers	T078	C1511983
27812347	678	686	database	T170	C0242356
27812347	732	734	SN	T023	C0038590
27812347	739	750	nigrosome-1	T025	C1512035
27812347	756	762	manual	T169	C0175674
27812347	763	775	segmentation	T059	C0200768
27812347	781	790	automated	T169	C0205554
27812347	791	803	segmentation	T059	C0200768
27812347	818	823	voxel	T077	C2700259
27812347	831	842	morphometry	T059	C0200760
27812347	844	866	Voxel intensity ratios	T081	C0392762
27812347	872	882	calculated	T052	C1441506
27812347	888	910	voxel intensity values	T081	C0392762
27812347	926	937	nigrosome-1	T025	C1512035
27812347	969	971	SN	T023	C0038590
27812347	973	999	Linear regression analyses	T081	C0023733
27812347	1024	1046	voxel intensity ratios	T081	C0392762
27812347	1056	1122	Movement Disorder Society-Unified Parkinson's Disease Rating Scale	T170	C3639714
27812347	1124	1133	MDS-UPDRS	T170	C3639714
27812347	1135	1145	sub-scores	T081	C0449820
27812347	1168	1174	manual	T169	C0175674
27812347	1175	1187	segmentation	T059	C0200768
27812347	1189	1206	linear regression	T081	C0023733
27812347	1241	1262	voxel intensity ratio	T081	C0392762
27812347	1280	1292	dorsolateral	T082	C2983598
27812347	1293	1295	SN	T023	C0038590
27812347	1300	1311	nigrosome-1	T025	C1512035
27812347	1335	1341	nBehav	T058	C1160858
27812347	1359	1363	nExp	T033	C0243095
27812347	1383	1392	automated	T169	C0205554
27812347	1393	1405	segmentation	T059	C0200768
27812347	1407	1424	linear regression	T081	C0023733
27812347	1463	1471	Subscore	T081	C0449820
27812347	1476	1482	nBehav	T058	C1160858
27812347	1499	1507	Subscore	T081	C0449820
27812347	1512	1516	nExp	T033	C0243095
27812347	1533	1538	Score	T081	C0449820
27812347	1543	1547	mExp	T040	C0026612
27812347	1568	1573	Score	T081	C0449820
27812347	1579	1584	mSign	T170	C3639714
27812347	1610	1615	voxel	T077	C2700259
27812347	1623	1644	morphometric approach	T059	C0200760
27812347	1646	1690	univariate simple linear regression analysis	T081	C0023733
27812347	1742	1748	nBehav	T058	C1160858
27812347	1765	1769	mExp	T040	C0026612
27812347	1788	1793	mSign	T184	C0037088
27812347	1809	1821	Neuroimaging	T060	C0679575
27812347	1822	1832	biomarkers	T201	C0005516
27812347	1859	1866	changes	T169	C0392747
27812347	1874	1885	nigrosome-1	T025	C1512035
27812347	1899	1908	MDS-UPDRS	T170	C3639714
27812347	1922	1931	indicator	T169	C1522602
27812347	1939	1947	severity	T080	C0439793
27812347	1951	1953	PD	T047	C0030567
27812347	1959	1980	voxel intensity ratio	T081	C0392762
27812347	1998	2010	dorsolateral	T082	C2983598
27812347	2011	2013	SN	T023	C0038590
27812347	2018	2029	nigrosome-1	T025	C1512035
27812347	2071	2088	complex behaviors	T033	C0474411
27812347	2154	2166	daily living	T056	C0001288
27812347	2168	2173	motor	T169	C1513492
27812347	2189	2201	daily living	T056	C0001288
27812347	2207	2218	motor signs	T184	C0037088
27812347	2222	2224	PD	T047	C0030567
27812347	2285	2292	changes	T169	C0392747
27812347	2300	2311	nigrosome-1	T025	C1512035
27812347	2334	2351	clinical measures	T201	C0683325
27812347	2355	2357	PD	T047	C0030567
27812347	2362	2369	changes	T169	C0392747
27812347	2377	2388	nigrosome-1	T025	C1512035
27812347	2441	2449	clinical	T080	C0205210
27812347	2450	2465	diagnostic tool	T060	C0430022
27812347	2470	2478	patients	T101	C0030705
27812347	2494	2496	PD	T047	C0030567